



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box. 1450 Alexandria, Viiginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,524	11/13/2001	Maximiliano Vasquez	011823-008120US	1601
20350	7590 08/24/2004		EXAM	INER
	ND AND TOWNSEN ARCADERO CENTER	EWOLDT, GERALD R		
EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834			ART UNIT	PAPER NUMBER
			1644	

DATE MAILED: 08/24/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/992,524	VASQUEZ ET AL.
Office Action Summary	Examiner	Art Unit
	G. R. Ewoldt, Ph.D.	1644
The MAILING DATE of this communication Period for Reply	n appears on the cover sheet wi	th the correspondence address
A SHORTENED STATUTORY PERIOD FOR RI THE MAILING DATE OF THIS COMMUNICATIO - Extensions of time may be available under the provisions of 37 CF after SIX (6) MONTHS from the mailing date of this communicatio - If the period for reply specified above is less than thirty (30) days, - If NO period for reply is specified above, the maximum statutory pr - Failure to reply within the set or extended period for reply will, by s Any reply received by the Office later than three months after the r earned patent term adjustment. See 37 CFR 1.704(b). Status	ON. FR 1.136(a). In no event, however, may a n. n. a reply within the statutory minimum of thirt eriod will apply and will expire SIX (6) MON statute, cause the application to become A.P.	eply be timely filed y (30) days will be considered timely. THS from the mailing date of this communication.
1) Responsive to communication(s) filed on 1	13 November 2001.	
	This action is non-final.	
3) Since this application is in condition for all closed in accordance with the practice und	owance except for formal matte der <i>Ex parte Quayle</i> , 1935 C.D.	ers, prosecution as to the merits is
Disposition of Claims	,	,
4) Claim(s) 1-13 is/are pending in the applica 4a) Of the above claim(s) is/are with 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-13 are subject to restriction and Application Papers 9) The specification is objected to by the Example of the specification is objected to be specification in the specification is objected to be specification in the specification is objected in the specification in the specification in the specification is objected in the specification in the	drawn from consideration. /or election requirement.	
10) The drawing(s) filed on is/are: a) = 1	accepted or b)□ objected to b	y the Examiner.
Applicant may not request that any objection to	the drawing(s) be held in abeyand	ce. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the cor 11) The oath or declaration is objected to by the	rrection is required if the drawing(se Examiner. Note the attached	s) is objected to. See 37 CFR 1.121(d). Office Action or form PTO-152.
riority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for fore a) All b) Some * c) None of: 1. Certified copies of the priority docume 2. Certified copies of the priority docume 3. Copies of the certified copies of the p application from the International Bur * See the attached detailed Office action for a line	ents have been received. ents have been received in Ap priority documents have been re reau (PCT Rule 17.2(a)).	plication No eceived in this National Stage
(ttachment/e)		
uttachment(s) Notice of References Cited (PTO-892)	Λ <u> </u>	(DTO 440)
Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/	mmary (PTO-413) Mail Date
) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/l Paper No(s)/Mail Date		ormal Patent Application (PTO-152)

DETAILED ACTION

- 1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
- I. Claims 1-11, drawn to a humanized immunoglobulin, classified in Class 530, subclass 387.3.
- II. Claims 12-13, drawn to a method of treating a patient suffering from a harmful immune response, classified in Class 424, subclass 133.1.
- 2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)).

In the instant case, the product as claimed can be used in materially different processes, such as for *in vitro* assays or for anti-idiotypic antibody generation.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, and differing subclasses, restriction for examination purposes as indicated is proper.
- 4. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.
- 5. The Examiner has required restriction between product and process claims. Where Applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312. In the event of rejoinder, the requirement for restriction

between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Applicant is advised, however, that to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until all elected product claims are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the Examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

G.R. Ewoldt, Ph.D. Primary Examiner Technology Center 1600

G.R. EWOLDT, PH.D. PRIMARY EXAMINER